CN102319245B - 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 - Google Patents
一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 Download PDFInfo
- Publication number
- CN102319245B CN102319245B CN201110190175.XA CN201110190175A CN102319245B CN 102319245 B CN102319245 B CN 102319245B CN 201110190175 A CN201110190175 A CN 201110190175A CN 102319245 B CN102319245 B CN 102319245B
- Authority
- CN
- China
- Prior art keywords
- repaglinide
- recipe quantity
- pvp
- preparation
- metformin hydrochloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 title claims abstract description 57
- 229960002354 repaglinide Drugs 0.000 title claims abstract description 57
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 229960004329 metformin hydrochloride Drugs 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 17
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 238000005550 wet granulation Methods 0.000 claims abstract description 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 239000000314 lubricant Substances 0.000 claims abstract description 4
- 239000000945 filler Substances 0.000 claims abstract description 3
- 239000000243 solution Substances 0.000 claims description 38
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 27
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical group CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 25
- 229960003194 meglumine Drugs 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 21
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 21
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 12
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 12
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 12
- 239000008188 pellet Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 abstract description 15
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 239000007767 bonding agent Substances 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 11
- 229960003105 metformin Drugs 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- HPWIKAVXRHCHPE-BQAIUKQQSA-N CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 Chemical compound CN(C)C(=N)N=C(N)N.C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 HPWIKAVXRHCHPE-BQAIUKQQSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000012738 dissolution medium Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011978 dissolution method Methods 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940103420 prandimet Drugs 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Chemical class 0.000 description 1
- 239000004375 Dextrin Chemical class 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Chemical class 0.000 description 1
- 229920000881 Modified starch Chemical class 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 238000010237 hybrid technique Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000594 mannitol Chemical class 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 repaglinide metformin hydrochloride compound Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110190175.XA CN102319245B (zh) | 2011-07-08 | 2011-07-08 | 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110190175.XA CN102319245B (zh) | 2011-07-08 | 2011-07-08 | 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102319245A CN102319245A (zh) | 2012-01-18 |
CN102319245B true CN102319245B (zh) | 2014-07-09 |
Family
ID=45447173
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110190175.XA Active CN102319245B (zh) | 2011-07-08 | 2011-07-08 | 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102319245B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018034627A1 (en) * | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103181923B (zh) * | 2011-12-29 | 2017-10-27 | 北京韩美药品有限公司 | 包含瑞格列奈的药物制剂及其制备方法 |
CN107184569A (zh) * | 2012-08-09 | 2017-09-22 | 迪纳米斯治疗公司 | 保持或改善对象健康、幸福和/或生理功能的方法 |
CN103768062B (zh) * | 2012-10-24 | 2016-10-19 | 北京万生药业有限责任公司 | 一种瑞格列奈和盐酸二甲双胍的复方制剂 |
CN103385878B (zh) * | 2013-07-24 | 2015-07-15 | 山东省医药工业研究所 | 瑞格列奈二甲双胍药用组合物及其制备方法 |
CN104337811A (zh) * | 2013-08-02 | 2015-02-11 | 江苏柯菲平医药股份有限公司 | 瑞格列奈-盐酸二甲双胍片及其制备方法 |
CN103705515B (zh) * | 2013-12-27 | 2016-05-11 | 华润赛科药业有限责任公司 | 含有瑞格列奈和盐酸二甲双胍的药物组合物的制备方法 |
CN104224783B (zh) * | 2014-09-19 | 2019-09-10 | 四川海思科制药有限公司 | 一种含瑞格列奈二甲双胍的药物组合物及其制备方法 |
CN104666341A (zh) * | 2015-01-30 | 2015-06-03 | 上海华源安徽锦辉制药有限公司 | 一种多维元素片及其混合制粒工艺 |
CN105769791B (zh) * | 2016-03-09 | 2018-08-10 | 上海丽珠制药有限公司 | 科洛曲片及其制备方法 |
CN106727554A (zh) * | 2016-12-20 | 2017-05-31 | 北京北陆药业股份有限公司 | 含瑞格列奈和盐酸二甲双胍的药用组合物及其制备方法 |
CN109512796A (zh) * | 2018-12-26 | 2019-03-26 | 甘肃普安制药股份有限公司 | 一种氨酚羟考酮胶囊填充方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131930A1 (en) * | 2006-05-13 | 2007-11-22 | Novo Nordisk A/S | Tablet formulation comprising repaglinide and metformin |
-
2011
- 2011-07-08 CN CN201110190175.XA patent/CN102319245B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007131930A1 (en) * | 2006-05-13 | 2007-11-22 | Novo Nordisk A/S | Tablet formulation comprising repaglinide and metformin |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018034627A1 (en) * | 2016-08-18 | 2018-02-22 | İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi | Pharmaceutical composition of antidiabetic tablet |
Also Published As
Publication number | Publication date |
---|---|
CN102319245A (zh) | 2012-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102319245B (zh) | 一种含有瑞格列奈和盐酸二甲双胍的组合物及其制备 | |
CN103845326B (zh) | 维格列汀与二甲双胍的复方组合物及其制备方法 | |
CN103845299A (zh) | 一种治疗心血管疾病的缓释片及其制备方法 | |
CN104622822A (zh) | 一种盐酸二甲双胍片剂组合物及其制备方法 | |
CN100484574C (zh) | 盐酸头孢他美酯分散片及其制备方法 | |
CN103181923B (zh) | 包含瑞格列奈的药物制剂及其制备方法 | |
CN102755301B (zh) | 格列美脲组合物片及其制备方法 | |
CN102688252A (zh) | 一种阿卡波糖口服固体制剂组合物及其制备方法 | |
CN106265641A (zh) | 一种含有维格列汀和二甲双胍的药物组合物及其制备方法 | |
CN111973565A (zh) | 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法 | |
CN101167731A (zh) | 含有二甲双胍和格列本脲的分散片及其制备方法 | |
CN103006594A (zh) | 一种格列美脲组合物及其制备方法 | |
CN105343028A (zh) | 一种诺氟沙星的药物组合物及其制备方法 | |
CN103271890A (zh) | 盐酸普拉克索胶囊及其制备方法 | |
CN100353943C (zh) | 乳酸氟罗沙星分散片及其制备方法 | |
CN103127022A (zh) | 一种别嘌醇复合型释药***及其制备方法 | |
CN113116892B (zh) | 含有瑞格列奈的药物组合物及其制备方法 | |
CN101433524A (zh) | 格列美脲片及其制备方法 | |
CN104224783B (zh) | 一种含瑞格列奈二甲双胍的药物组合物及其制备方法 | |
CN105663131B (zh) | 一种瑞格列奈二甲双胍片药物组合物及其制备方法 | |
CN100560069C (zh) | 一种米格列奈钙制剂及其检测方法 | |
CN101721414B (zh) | 含有盐酸吡格列酮和盐酸二甲双胍的组合物及其制备 | |
CN113616613A (zh) | 一种治疗糖尿病用药二甲双胍格列吡嗪复方片剂及其制备方法 | |
CN102218064B (zh) | 瑞格列奈和二甲双胍为活性成份的药用组合物及制备方法 | |
CN102228448A (zh) | 头孢呋辛酯片及其全粉末直接压片方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 310012 West Lake international science and technology building, No. 391 Wen two road, Hangzhou, Zhejiang, C910, Xihu District Applicant after: HANGZHOU HUADONG MEDICINE GROUP NEW MEDICINE RESEARCH INSTITUTE CO., LTD. Address before: 310012 West Lake international science and technology building, No. 391 Wen two road, Hangzhou, Zhejiang, C910, Xihu District Applicant before: Hangzhou Huadong Medicine Group Biological Engineering Research Institute Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: HUADONG MEDICINE BIOLOGICAL ENGINEERING RESEARCH INSTITUTE CO., LTD. TO: NEW DRUG RESEARCH INSTITUTE CO., LTD. OF HANGZHOU HUADONG MEDICINE GROUP |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120118 Assignee: Hangzhou Huadi Pharmaceutical Technology Co.,Ltd. Assignor: Hangzhou Huadong Medicine Group Biopharmaceutical Co.,Ltd. Contract record no.: X2021330000100 Denomination of invention: The invention relates to a composition containing repaglinide and metformin hydrochloride and a preparation method thereof Granted publication date: 20140709 License type: Common License Record date: 20210820 |